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Abstract
Background: Glyceraldehyde 3-phosphate dehydrogenases (GAPDHs) are cytoplasmic glycolytic enzymes, which
although lacking identifiable secretion signals, have also been found localized to the surface of several bacteria
(and some eukaryotic organisms); where in some cases they have been shown to contribute to the colonization
and invasion of host tissues. Neisseria meningitidis is an obligate human nasopharyngeal commensal which can
cause life-threatening infections including septicaemia and meningitis. N. meningitidis has two genes, gapA-1 and
gapA-2, encoding GAPDH enzymes. GapA-1 has previously been shown to be up-regulated on bacterial contact
with host epithelial cells and is accessible to antibodies on the surface of capsule-permeabilized meningococcal
cells. The aims of this study were: 1) to determine whether GapA-1 was expressed across different strains of
N. meningitidis; 2) to determine whether GapA-1 surface accessibility to antibodies was dependant on the presence
of capsule; 3) to determine whether GapA-1 can influence the interaction of meningococci and host cells,
particularly in the key stages of adhesion and invasion.
Results: In this study, expression of GapA-1 was shown to be well conserved across diverse isolates of Neisseria
species. Flow cytometry confirmed that GapA-1 could be detected on the cell surface, but only in a siaD-knockout
(capsule-deficient) background, suggesting that GapA-1 is inaccessible to antibody in in vitro-grown encapsulated
meningococci. The role of GapA-1 in meningococcal pathogenesis was addressed by mutational analysis and
functional complementation. Loss of GapA-1 did not affect the growth of the bacterium in vitro. However, a GapA-
1 deficient mutant showed a significant reduction in adhesion to human epithelial and endothelial cells compared
to the wild-type and complemented mutant. A similar reduction in adhesion levels was also apparent between a
siaD-deficient meningococcal strain and an isogenic siaD gapA-1 double mutant.
Conclusions: Our data demonstrates that meningococcal GapA-1 is a constitutively-expressed, highly-conserved
surface-exposed protein which is antibody-accessible only in the absence of capsule. Mutation of GapA-1 does not
affect the in vitro growth rate of N. meningitidis, but significantly affects the ability of the organism to adhere to
human epithelial and endothelial cells in a capsule-independent process suggesting a role in the pathogenesis of
meningococcal infection.
Background
Neisseria meningitidis is an obligate human commensal
that is spread from person to person by droplet infec-
tion. The organism colonizes the nasopharyngeal
mucosa in an asymptomatic manner, a condition known
as carriage [1]. Under certain circumstances the bacteria
can invade the epithelial layers to gain access to the
bloodstream, which can result in a wide spectrum of
clinical syndromes ranging from transient bacteraemia
to rapidly fatal sepsis. Bacteria may also interact with
cerebrovascular endothelial cells and cross the blood-
cerebrospinal fluid barrier to cause meningitis [2]. To
reach the meninges, N. meningitidis must interact with
two cellular barriers and adhesion to both epithelial and
endothelial cells are crucial stages of infection. Adhesion
to both cell types is complex and remains poorly under-
stood, but initial attachment is mediated by type IV pili,
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of pili and capsule: structures that otherwise hinder inti-
mate adhesion, in a process that may involve the CrgA
protein [3]. Intimate interaction between bacterial mem-
brane components and their respective host cell surface
receptors may subsequently lead to uptake of the bacter-
ial cells (reviewed in [4]).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
is a glycolytic enzyme which catalyzes the conversion of
glyceraldehyde 3-phosphate to 1, 3-diphosphoglycerate.
The most common form is the NAD+-dependent
enzyme (EC 1.2.1.12) found in all organisms studied so
far and which is usually located in the cytoplasm. In
addition to its metabolic function, studies have demon-
strated that GAPDH is present on the surface of several
microbial pathogens and may facilitate their colonization
and invasion of host tissues by interacting directly with
host soluble proteins and surface ligands. Surface locali-
zation of GAPDH was first demonstrated in the Gram-
positive pathogen, Streptococcus pyogenes. In this organ-
ism, surface-exposed GAPDH binds several mammalian
proteins including the uPAR/CD87 membrane protein
on pharyngeal cells [5-8], regulates intracellular host cell
signalling events [9] and contributes to host immune
evasion [10]. GAPDH was subsequently identified on
the surface of other Gram-positive bacteria including
staphylococci [11,12], S. agalactiae [13], S. pneumoniae
[14] and Listeria monocytogenes [15]. In addition, surface
localization of GAPDH has been reported in enterohe-
morrhagic (EHEC) and enteropathogenic (EPEC) Escher-
ichia coli; the protein of these pathogens has been
observed to bind to human plasminogen and fibrinogen,
suggesting a role in pathogenesis [16]. Similar to the
surface-localized GAPDHs from other species, the
EHEC and EPEC GAPDH proteins possess NAD-ribosy-
lating activity [17]. In Mycoplasma genitalium, surface-
associated GAPDH is important for adhesion to human
mucin [18], and in Lactobacillus plantarum,an o r m a l
inhabitant of the human gastrointestinal tract, GAPDH
was shown to be involved in adherence to gastric mucin
and Caco-2 cells [19,20]. Interestingly, the major fim-
briae of Porphyromonas gingivalis bind to GAPDH on
the surface of several oral streptococci, and this interac-
tion is important for colonization of the oral cavity [21].
Fungi also express GAPDH on their cell surface, for
example, the GAPDH of Candida albicans was shown
to be associated with the cell wall and involved in med-
iating adhesion to fibronectin, laminin and plasminogen
[22-24]. GAPDH has also been found on the surface of
the single-celled protozoan, Trichomonas vaginalis,a n d
shown to bind extracellular matrix components, includ-
ing fibronectin [25].
The N. meningitidis MC58 genome sequence contains
two putative GAPDH-encoding genes (gapA-1 and
gapA-2) which share 50% nucleotide identity [26].
Expression of GapA-1 (but not GapA-2) on the menin-
gococcal cell surface was previously found to be up-
regulated following contact with human epithelial cells,
although no function was ascribed to this observation
[27]. Two other cytoplasmic glycolytic enzymes, despite
lacking identifiable secretion signals, anchoring motifs
or hydrophobic membrane-spanning regions (hence the
term ‘anchorless proteins’), have been found localized to
the surface of N. meningitidis. These are enolase, which
acts to recruit plasminogen onto the bacterial surface
[28], and fructose-1, 6-bisphosphate aldolase (FBA),
which we have recently demonstrated is required for
optimal adhesion to human cells [29]. The aim of this
study was to determine whether GapA-1 can influence
the interaction of meningococci and host cells.
Methods
Bacterial strains and growth conditions
E. coli TOP10F’ and BL21(DE3)pLysS (Table 1) were used
for the expression of 6 × histidine-tagged recombinant
GapA-1 encoded by plasmid pDT-GapA1 (Table 1). E. coli
JM109 was used as host for the construction of mutagenic
and complementation plasmids, pSAT-8 and pSAT-14
respectively. E. coli strains were grown at 37°C in LB broth
or on LB agar supplemented, where appropriate, with
ampicillin (100 μgm l
-1), kanamycin (30 μgm l
-1)o re r y -
thromycin (200 μgm l
-1). Strains of Neisseria (Table 1 and
Additional file 1) were grown at 37°C, air plus 5% CO2, on
Brain Heart Infusion (BHI) agar supplemented with 1%
Vitox (Thermo Fisher Scientific, Waltham, MA) and kana-
mycin (50 μgm l
-1) or erythromycin (5 μgm l
-1)w h e r e
appropriate.
DNA manipulation
Genomic DNA was extracted from N. meningitidis using
t h eD N e a s yT i s s u ek i t( Q i a gen, Crawley, UK). Plasmid
DNA was prepared using the QIAprep Spin kit (Qiagen,
Crawley, UK). All enzymes were purchased from Roche
Diagnostics (Indianapolis, IN) and used according to the
manufacturer’s instructions. DNA sequencing was carried
out at the School of Biomedical Sciences (University of
Nottingham) on an ABI 377 automated DNA sequencer.
Preparation of recombinant GapA-1 and aGapA-1 rabbit
polyclonal antiserum
The gapA-1 gene was amplified from N. meningitidis
MC58 using oligonucleotide primers NMB0207(F) and
NMB0207(R) (Table 2). The amplicon was ligated into
pCRT7/NT-TOPO and the resulting plasmid, pDT-
GapA1, used to transform E. coli BL21(DE3)pLysS.
Transformants were grown to log phase, induced for
3hw i t h1m Mi s o p r o p y lb-D-1-thiogalactopyranoside
(IPTG) and harvested by centrifugation. Recombinant
Tunio et al. BMC Microbiology 2010, 10:280
http://www.biomedcentral.com/1471-2180/10/280
Page 2 of 106 × histidine-tagged GapA-1 was then affinity-purified
under denaturing conditions. Briefly, the culture pellet
was dissolved in 20 ml lysis buffer (100 mM NaH2PO4,
10 mM Tris-Cl, 10 mM Imidazole and 8 M Urea, pH
8.0) and disrupted by sonication using a MSE Soniprep
150 for 10 cycles (each cycle consisting of a 10 s burst
followed by a 10 s cooling period). The cell lysates was
then mixed with 1 ml HisPur™ Cobalt Resin (Thermo
Fisher Scientific, Waltham, MA) and incubated over-
night at 4°C. The lysate-resin mixture was then applied
to the column, and washed with 100 mM NaH2PO4,
10 mM Tris-Cl, 20 mM Imidazole, 8 M Urea, pH 6.3.
Bound proteins were then eluted in elution buffer
(100 mM NaH2PO4, 10 mM Tris-Cl, and 8 M Urea, pH
4.5). Eluted fractions were resolved by SDS-PAGE, and
recombinant GapA-1 excised from the gel, transferred
to Mini D-Tube dialyzers (Merck Biosciences, Darm-
stadt, Germany) and electro-eluted according to the
recommendations of the manufacturer. Recombinant
GapA-1 was then concentrated using YM-30 Centrifugal
Table 1 Bacterial strains and plasmids
Strain or plasmid Description Source or reference
Strains
E. coli
JM109 Cloning strain Promega, Madison, WI
TOP10F’ Cloning strain Invitrogen, Carlsbad, CA
BL21(DE3)pLysS Expression strain Invitrogen, Carlsbad, CA
N. meningitidis
MC58 wild-type serogroup B strain [26]
MC58ΔgapA-1 gapA-1 deletion and replacement with kanamycin cassette This study
MC58ΔgapA-1
gapA-1
Ect
MC58ΔgapA-1 complemented with an ectopic copy of gapA-1 This study
MC58ΔsiaD siaD deletion and replacement with erythromycin cassette C. Tang Imperial College
MC58ΔsiaD
ΔgapA-1
siaD and gapA-1 deficient strain generated from MC58ΔsiaD using pSAT-8 This study
Plasmids
pCRT7/NT-TOPO Cloning vector encoding resistance to ampicillin Invitrogen, Carlsbad, CA
pDT-GapA1 MC58 gapA-1 gene cloned in pCRT7-TOPO This study
pGEM-T Easy Cloning vector encoding resistance to ampicillin Promega, Madison, WI
pSAT-6 3-kb fragment spanning the MC58 gapA-1 region cloned in pGEM-T Easy This study
pJMK30 Source of kanamycin resistance cassette [43]
pSAT-8 pSAT-6 containing the kanamycin resistance cassette in the same orientation as the
deleted gapA-1 gene
This study
pSAT-12 Complementation vector containing cbbA and encoding resistance to erythromycin [29]
pSAT-14 pSAT-12 containing gapA-1 in place of the deleted cbbA This study
Table 2 List of primers used in this study
Primer DNA sequence* Restriction site
Expression
NMB0207(F) CGCGGATCCATGGGCATCAAAGTCGCCATC BamHI
NMB0207(R) CGCGTCGACTTATTTGAGCGGGCGCACTTC SalI
Mutagenesis
NMB0207(R)FL GAGAACTGTCATGCGTATTCC
NMB0207(F)FL CCAAACCCAATGCCGCGAATG
gapA1_M1(IR) GCGAGATCTGCAACAAACCGTC BglII
gapA1_M2(IF) GCGAGATCTGGTTTGTTCCTTTGTTGAGGG BglII
Complementation
pSAT-12iPCR(IF) CGCAGATCTGATACCCCCGATGAC BglII
pSAT-12iPCR(IR) CGCAGATCTCATTTGTGTC TCCTTGG BglII
gapA1_Comp(F)2 CGCGGATCCATGGGCATCAAAGTC BamHI
gapA1_Comp(R)2 CGCGGATCCTTTGTTTGACGGTTTGTTG BamHI
*All primers were designed from the N. meningitidis MC58 genome sequence. Sequences in bold identify restriction enzyme sites.
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antiserum against purified recombinant GapA-1, a New
Zealand White female rabbit was immunized subcuta-
neously four times at 2-week intervals with 30 μgo f
protein emulsified in Freund’s complete (first immuniza-
tion only) or incomplete adjuvant.
SDS-PAGE and immunoblotting
Proteins were electrophoretically separated using 10%
polyacrylamide gels (Mini-Protean III; Bio-Rad, Her-
cules, CA) and were stained using SimplyBlue Safestain™
(Invitrogen, Carlsbad, CA) or transferred to nitrocellu-
lose membranes as previously described [30]. Mem-
branes were probed with mouse anti-pentahistidine
antibody (Qiagen, Crawley, UK) or rabbit primary anti-
body diluted 1:10,000 & 1:1000 respectively in blocking
buffer (5% [wt/vol] non fat dry milk, 0.1% [vol/vol]
Tween 20 in 1 × phosphate-buffered saline [PBS]) and
incubated for 2 h. After being washed in PBS with 0.1%
Tween 20 (PBST), membranes were incubated for 2 h
with 1:30,000-diluted goat anti-mouse (or anti-rabbit)
IgG-alkaline phosphatase conjugate (Sigma-Aldrich, St.
Louis, MI). After washing with PBST, blots were devel-
oped using BCIP/NBT-Blue liquid substrate (Sigma-
Aldrich, St. Louis, MI).
Construction of MC58ΔgapA-1
A ca. 3 kb fragment of DNA consisting of the gapA-1 gene
and flanking DNA was amplified using NMB0207(F)FL
and NMB0207(R)FL (Table 2) from N. meningitidis MC58
chromosomal DNA. The amplified DNA was cloned into
pGEM-T Easy to generate pSAT-6 (Table 1). This was
then subject to inverse PCR using primers gapA1_M1(IR)
and gapA1_M2(IF) (Table 2) resulting in the amplification
of a 5 kb amplicon in which the gapA-1 coding sequence
was deleted and a unique BglII site had been introduced.
The BglII site was used to introduce a kanamycin resis-
tance cassette from pJMK30 (Table 1) in place of gapA-1.
One of the resulting plasmids, pSAT-8, containing the
resistance cassette in the same orientation as the deleted
gene, was confirmed by restriction digestion and sequen-
cing and subsequently used to mutate meningococcal
strains by natural transformation and allelic exchange as
previously described [31]. Mutation of gapA-1 was con-
firmed by PCR analysis and immunoblotting.
Complementation of gapA-1
Plasmid pSAT-12, which we previously used to comple-
ment the meningococcal cbbA gene [29] was subjected
to inverse PCR using the primers pSAT-12iPCR(IF) and
pSAT-12iPCR(IR) (Table 2). This resulted in deletion of
the cbbA coding sequence but leaving the upstream
cbbA-promoter sequence intact and introduced a unique
BglII site to facilitate the cloning of gapA-1 downstream
of the promoter. The gapA-1 coding sequence was
amplified from strain MC58 using the primers gapA1_-
Comp(F)2 and gapA1_Comp(R)2 (Table 2) incorporat-
ing BamHI-sites into the amplified fragment. The
BamHI-digested fragment was then introduced into the
BglII site to yield pSAT-14. This vector therefore con-
tained the gapA-1 coding sequence under the control of
the cbbA promoter and downstream of this, an erythro-
mycin resistance gene. These elements were flanked by
the MC58 genes NMB0102 and NMB0103. pSAT-14
was then used to transform MC58ΔgapA-1 by natural
transformation, thus introducing a single chromosomal
copy of gapA-1 under the control of the cbbA promoter
and the downstream erythromycin resistance cassette in
the intergenic region between NMB0102 and NMB0103.
Insertion of the gapA-1 gene and erythromycin resis-
tance cassette at the ectopic site was confirmed by PCR
analysis and sequencing.
Flow cytometry
These experiments were performed essentially as pre-
viously described [29]. Briefly, 1 × 10
7 CFU aliquots of
N. meningitidis were incubated for 2 h with rabbit anti-
GapA-1-specific polyclonal antiserum (RaGapA-1)
(1:500 diluted in PBS containing 0.1% BSA, 0.1% sodium
azide and 2% foetal calf serum) and untreated cells were
used as a control. Cells were washed with PBS and incu-
bated for 2 h with goat anti-rabbit IgG-Alexa Fluor 488
conjugate (Invitrogen, Carlsbad, CA; diluted 1:50 in PBS
containing 0.1% BSA, 0.1% sodium azide and 2% foetal
calf serum). Again, untreated cells were used as a con-
trol. Finally, the samples were washed before being fixed
in 1 ml PBS containing 0.5% formaldehyde. Samples
were analyzed for fluorescence using a Coulter Altra
Flow Cytometer. Cells were detected using forward and
log-side scatter dot plots, and a gating region was set to
exclude cell debris and aggregates of bacteria. A total of
50,000 bacteria (events) were analyzed.
Association and invasion assays
Association and invasion assays were performed essen-
tially as previously described [29]. Briefly, human brain
microvascular endothelial (HBME) or HEp-2 cells were
grown to confluence in 24-well tissue culture plates and
infected with approximately 1 × 10
6 CFU of log-phase
meningococci (multiplicity of infection of 10 bacteria per
cell) and incubated for 2 h (association) or 4 h (invasion)
in 5% CO2 at 37°C. To assess totalc e l la s s o c i a t i o n ,
monolayers were washed, then disrupted and homoge-
nized in 1 ml 0.1% saponin in PBS. To assess invasion,
monolayers were further incubated in DMEM containing
gentamicin (100 μgm l
-1) for 2 h. Prior to further steps,
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plated out to confirm killing of extra-cellular bacteria.
Furthermore, the susceptibility of all meningococcal
strains to gentamicin at 100 μgm l
-1 was confirmed prior
to testing. Monolayers were then washed, disrupted and
homogenized in 1 ml 0.1% saponin in PBS. Meningococci
were enumerated by serial dilution of the homogenized
suspensions and subsequent determination of colony-
forming units by plating aliquots from appropriate dilu-
tions of the lysates on agar. All association and invasion
assays were repeated at least three times. Statistical sig-
nificance was measured using a two-tailed Student t-test.
Protein and nucleic acid sequence analysis
Public databases containing previously published protein
and DNA sequences were searched using the BLAST
and PSI-BLAST programs available at http://blast.ncbi.
nlm.nih.gov/Blast.cgi. The genome database of N.
meningitidis MC58 was interrogated at http://cmr.jcvi.
org/cgi-bin/CMR/GenomePage.cgi?org=gnm. Sequence
homology data were obtained using the CLUSTALX
software (http://www.clustal.org/). Protein secretion sig-
nals were analyzed using the SignalP 3.0 server available
at http://www.cbs.dtu.dk/services/SignalP/[32]. GenBank
accession numbers for the gapA-1 sequences analyzed in
this study are as follows: YP_97432562 (FAM18),
YP_00160027 (ST-4821 strain 053442), YP_002341615
(Z2491), YP_208807 (gonococcal strain FA1090) and
ZP_03723143 (N. lactamica ATCC 23970).
Results
Sequence analysis of gapA-1, flanking DNA and GapA-1
protein
In N. meningitidis strain MC58, gapA-1 (locus tag
NMB0207) is located downstream of, and in the oppo-
site orientation to, aat (NMB0206) encoding the leucyl/
phenylalanyl-tRNA-protein transferase and upstream of,
and in the same orientation as, NMB0208, which
encodes an electron transport protein, ferredoxin (4Fe-
4S-type). A similar genomic arrangement is present in
the meningococcal strains Z2491 [33], FAM18 [34] and
053442 [35]. The sequences of gapA-1 in these strains
are >97% identical to the MC58 gapA-1 gene. Addition-
ally, gapA-1 orthologues are found in the gonococcal
strain FA1090 (99% identical) and N. lactamica strain
ST640 (93% identical). At the amino acid level, the
highly conserved GAPDH active site was identified
(
153ASCTTNCL
160), and GapA-1 shows significant
homology to GAPDH enzymes from higher organisms,
including the human GAPDH enzyme (45% identity).
Despite its demonstrated presence on the bacterial sur-
face [27], GapA-1 of N. meningitidis was not predicted
to be an exported protein by the SignalP-HMM and
-NN programs.
Cloning, expression and purification of recombinant
GapA-1
The gapA-1 gene from MC58 was cloned into the
expression vector pCRT7/NT-TOPO to facilitate the
expression and subsequent purification of 6 × histidine-
tagged recombinant GapA-1 (Figure 1a). This was used
to generate RaGapA-1. Immunoblot analysis confirmed
that RaGapA-1 and anti-pentahistidine antibodies both
reacted to the purified recombinant GapA-1 (Figure 1b
&1c).
Construction of an N. meningitidis gapA-1 null mutant
strain
To examine the roles of GapA-1 in the meningococcus,
a gapA-1 knockout derivative of N. meningitidis MC58
was generated. Immunoblotting using RaGapA-1
showed that GapA-1 could be detected in whole cell
lysates of wild-type but not MC58ΔgapA-1 (Figure 2,
l a n e s1&2 )c o n f i r m i n gt h a tG a p A - 1w a se x p r e s s e d
under the conditions used and that expression had been
abolished in the mutant. This analysis further confirmed
that the RaGapA-1 sera did not recognize GapA-2 (37-
kDa) under the conditions used. To further confirm that
the immuno-reactive protein was GapA-1, a wild-type
copy of gapA-1 was introduced in trans into
MC58ΔgapA-1 using plasmid pSAT-14 (Table 1). Intro-
duction of gapA-1 at an ectopic site restored GapA-1
expression (Figure 2, lane 3). Further immunoblot ana-
lyses using a panel of 14 N. meningitidis strains (Addi-
tional file 1) including representatives of differing
serogroups and MLST-types showed that GapA-1
expression was conserved across all strains (data not
shown). Expression was also conserved in N. gonor-
rhoeae FA1090 (data not shown). These data comple-
ment in silico p r e d i c t i o n st h a tG a p A - 1i su n i v e r s a l l y
present and suggests that GapA-1 is constitutively-
expressed across pathogenic Neisseria species.
Figure 1 SDS-PAGE and immunoblot analysis of recombinant
GapA-1. SDS-PAGE analysis confirms the purity of the recombinant
GapA-1 purified under denaturing conditions (a). Immunoblot
analysis shows that recombinant GapA-1 is recognized by RaGapA-1
(b) and anti-pentahistidine antibodies (c).
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antibodies in the absence of capsule
Grifantini et al showed using flow cytometry that GapA-1
was accessible to specific antibodies on the surface of
meningococci [27]. However, the methodology used
involved pre-treatment of the cells with 70% ethanol to
permeabilize the capsule, making it unclear whether
GapA-1 was accessible to antibodies in encapsulated bac-
teria. We used RaGapA-1 antibodies to probe wild-type,
MC58ΔgapA-1 and MC58ΔsiaD (capsule-deficient) strains
and analyzed them by flow cytometry (Figure 3). MC58
wild-type and MC58ΔgapA-1 treated with RaGapA-1 fol-
lowed by anti-rabbit IgG-Alexa Fluor 488 conjugate
showed no demonstrable shift in fluorescence signal com-
pared to the same strains incubated with RaGapA-1 or
secondary antibody alone showing that GapA-1 was not
detectable on whole cells of these strains (Figure 3a &3b).
However, identical experiments using MC58ΔsiaD
demonstrated a clear shift in fluorescence when cells were
treated with RaGapA-1 followed by anti-rabbit IgG-Alexa
Fluor 488 conjugate (Figure 3c). This demonstrated that,
in the absence of capsule, surface exposed GapA-1 was
accessible to antibody. From the MC58ΔsiaD cells probed
with both antibodies, 25% were found in the M2 region
(Figure 3c), suggesting that in broth-grown cells unex-
posed to human epithelial cells only a minority of the
population had GapA-1 was present on the cell surface.
Pre-immune sera showed no reactivity against wild-type
MC58 or MC58ΔsiaD,a n dR aGapA-1 specifically recog-
nized only GapA-1 in immunoblot experiments confirm-
ing that the binding of RaGapA-1 to MC58ΔsiaD
observed by flow cytometry was GapA-1 specific.
GapA-1 is required for optimal adhesion to host cells
The capacity of the wild-type, GapA-1 mutant and com-
plemented mutant strains to associate with, and invade
into human brain microvascular endothelial (HBME)
cells were then determined. GapA-1 deficient meningo-
cocci had a significantly reduced capacity to adhere to
monolayers of HBME cells (Figure 4). No significant
reduction was observed in the ability of the GapA-1
mutant to invade monolayers of HBME cells (data not
shown). Similar results were also obtained using HEp-2
cells confirming that the effect was not limited to
endothelial cells (data not shown). To confirm that the
observed effects were not due to an impairment of in
vitro growth, the growth rate of the strains was com-
pared by measuring the optical density at 600 nm
(OD600) and determining the viable counts of broth cul-
tures sampled during exponential growth over 24 h in
triplicate on three separate occasions. No significant dif-
ference between strains was observed (data not shown).
The effect of GapA-1 mutation on meningococcal
adhesion is capsule-independent
Our experiments demonstrate clearly that GapA-1
increased the ability of meningococci to adhere to host
cells (Figure 4), suggesting a role in pathogenesis. How-
ever, flow cytometry indicated that GapA-1 is made inac-
cessible to antibodies on the surface of meningococci by
capsule (Figure 3). In order to determine whether capsule
expression influences the ro l eo fG a p A - 1i na d h e s i o nt o
host cells we constructed a gapA-1 deficient derivative of
MC58ΔsiaD, which does not express a capsule. After
confirming that GapA-1 expression had been abolished
in MC58ΔsiaD ΔgapA-1 (Figure 2, lanes 4 & 5), we
determined the capacity of both strains to associate with
HBME cells. GapA-1 deficient non-encapsulated menin-
gococci had a significantly reduced capacity to adhere to
monolayers of HBME cells compared to the parent strain
(Figure 5), confirming our observation that GapA-1 is
required for optimal host cell adhesion. However, this
reduction was not enhanced in the non-encapsulated
background, indicating that the role of gapA-1 in the
Figure 2 Immunoblot analysis of whole cell proteins from N. meningitidis using RaGapA-1. Analysis of MC58 wild-type, ΔgapA-1 mutant
derivative and complemented mutant reveals the absence of GapA-1 in the ΔgapA-1 mutant preparation. Similar analysis shows the abolition of
GapA-1 expression in the MC58ΔsiaD ΔgapA-1 mutant compared to the parental MC58ΔsiaD strain.
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of capsule. In summary, these experiments show that
GapA-1 plays a role in the adherence of N. meningitidis
with human cells in a capsule-independent manner.
Discussion
It is now apparent that many of the classical cytoplasmic
house-keeping enzymes, including enolase, FBA and
Figure 3 Flow cytometry of MC58 wild-type (a), MC58ΔgapA-1
(b) or MC58ΔsiaD (c) for GapA-1 surface localization. Cells were
stained with RaGapA-1 (primary alone), anti-rabbit IgG-Alexa Fluor
488 conjugate (secondary alone) or both. Fluorescence was
displayed as a histogram. In panel c, the histogram area in M2
represents the population of fluorescently labelled meningococci.
Figure 4 MC58ΔgapA-1 has a reduced ability to associate with
HBMEs compared to the wild-type or complemented strains.T h e
number of GapA-1-deficient meningococci associating was
significantly lower than the wild-type (*P = 0.0018). Mean levels shown
from three independent experiments, each using triplicate wells. Bars
denote standard deviation. Cfu denotes colony forming units.
Figure 5 MC58ΔsiaD ΔgapA-1 has a reduced ability to
associate with HBME cells compared to MC58ΔsiaD. The
number of MC58ΔsiaD ΔgapA-1 cells associating was significantly
lower than the capsule null (*P = 0.0008). Mean levels shown from
three independent experiments, each using triplicate wells. Bars
denote standard deviation. Cfu denotes colony forming units.
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pathogens, where they exhibit various functions, unre-
lated to their housekeeping roles [36-38]. Currently,
there is considerable interest in identifying the addi-
tional roles of these bacterial glycolytic enzymes. In
N. meningitidis, enolase was recently shown to be a sur-
face-localized protein, where it acts to recruit plasmino-
gen onto the bacterial surface [28]. In addition, we have
recently demonstrated that FBA is also a partially sur-
face-localized protein and is required for optimal adhe-
sion to human cells through an unknown mechanism
[29]. Furthermore, it is noteworthy that GAPDH is also
a multi-functional protein in eukaryotic cells. For exam-
ple, in addition to its role in central metabolic pathways,
GAPDH is involved in controlling cell survival by delay-
ing apoptosis via the inhibition of caspase-dependant
proteolysis [39]. This raises the possibility that GAPDH
on the surface of invasive bacterial pathogens such as
N. meningitidis may influence intracellular processes of
host cells to the advantage of the invading organism
(including delaying apoptosis).
In our study, attempts to purify GapA-1 under native
conditions were unsuccessful. Therefore, recombinant
GapA-1 was purified under denaturing conditions in
order to raise antiserum, but it was not possible to
determine whether this protein had enzymatic activity.
Rabbit polyclonal GapA-1 antiserum was used for
immunoblot analysis of whole cell proteins from differ-
ent clinical isolates of known MLST-type. These strains
were representatives from lineages commonly causing
invasive meningococcal disease. This showed that they
all express GapA-1 suggesting that GapA-1 is constitu-
tively-expressed in N. meningitidis. A GapA-1 knock-out
mutant was created in N. meningitidis strain MC58 to
facilitate studies of the potential role of GapA-1 in the
pathogenesis of meningococcal disease. The GapA-1
mutant grew at the same rate (in broth culture and on
solid media) as the wild-type and the complemented
mutant strains, demonstrating that GapA-1 is not
required for growth of the meningococcus under
in vitro conditions. No differences in either colony or
bacterial cell morphology (using light microscopy) were
observed.
In a previous study, Grifantini et al. used microarrays
to show that expression of gapA-1 was up-regulated in
meningococcal strain MC58 (4.8-fold) following contact
for 30 min with human 16HBE14 epithelial cells [27].
Subsequent flow cytometry experiments showed that
GapA-1 could be detected on the cell surface of free
grown and adherent meningococci [27]. However, the
methodology used involved a pre-treatment of cells with
70% ethanol to permeabilize the capsule layer, thus
making it unclear if GapA-1 is antibody-accessible in
encapsulated meningococci. In our study, GapA-1 could
only be detected on the meningococcal cell surface in
mutants lacking capsule, suggesting that GapA-1 is
usually masked by this structure.
In our adhesion experiments using siaD-knockout
meningococci, the GapA-1 mutant strain exhibited a
similarly significantly reduced capacity to adhere to host
cells compared to the GapA-1 mutant in an encapsulated
strain suggesting that the presence of capsule does not
affect the role of GapA-1 in the adhesion process. It is
not obvious why the influence of GapA-1 on adhesion is
not itself modulated by the presence of masking capsule
since the removal of capsule does increase the ability of
meningococci to bind host cells via outer membrane
adhesins [4]. In our adhesion experiments the binding of
strains lacking capsule was approximately two-fold
higher than the cognate encapulsulated strains (Figure 4
&5). This agrees with previous studies comparing the
adherence of encapsulated and non-capsulated serogroup
B meningococci to macrophages and buccal epithelial
cells, where four-fold and less than two-fold increases,
respectively, in adhesion were seen when capsule produc-
tion was abolished [40,41]. Thus, it is possible that the
influence of surface-localised GapA-1 on adhesion to
h o s tc e l l si si n d i r e c t ,p o s s i b l yi n v o l v i n gi t se n z y m a t i c
activity, and that a direct interaction of GapA-1 with
the host cell surface is not required. Alternatively,
capsule expression in meningococci is known to be
down-regulated following the initial type IV pilus depen-
dant-contact with host cells in order to facilitate intimate
adherence [3]. Thus, we hypothesize that surface-
localised GapA-1 may be unmasked following this change
allowing it to influence subsequent steps in adhesion.
The observation that GapA-1 is detectable on the
meningococcal cell surface suggests that GapA-1 is
actively translocated to the outer membrane. An alterna-
tive hypothesis is that GapA-1 is released from lysed
cells and recruited back onto the surface of intact
meningococci. This maybe unlikely given the recent
work on L. plantarum which showed that provoked cell
lysis did not lead to re-association of GAPDH onto the
cell surface [42]. Instead, it was suggested that changes
in plasma membrane permeability during the growth
cycle may be involved in the movement of GAPDH
o n t ot h ee x t e r n a ls u r f a c eo ft h ep l a s m am e m b r a n ei n
this Gram-positive organism [42]. Clearly, such a
mechanism could only account for periplasmic localiza-
tion in a Gram-negative organism. We are currently
investigating how GapA-1 is localized to the cell surface
in N. meningitidis.
Conclusions
Meningococcal GapA-1 is a constitutively-expressed,
highly-conserved surface-exposed protein which is anti-
body-accessible only in the absence of capsule. Mutation
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Page 8 of 10of GapA-1 does not affect the in vitro growth rate of N.
meningitidis, but significantly affects the ability of the
organism to adhere to human epithelial and endothelial
cells in a capsule-independent process suggesting a role
in the pathogenesis of meningococcal infection.
Additional material
Additional file 1: Isolates of N. meningitidis examined for the
expression of GapA-1.
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